A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.
The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline outlining the use of external beam radiation therapy (EBRT) to treat adult patients with primary liver cancers. The guidelines emphasize multidisciplinary care and provide evidence-based recommendations on indications, dosing, techniques, and trea...
The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.
A meta-analysis of seven randomized trials found that Black men with localized prostate cancer had lower recurrence, metastasis, and mortality rates compared to white men. The study challenges the common belief that Black men with prostate cancer have a worse prognosis.
A Phase 2 clinical trial showed sotorasib can shrink tumors and achieve disease control in heavily pretreated patients with advanced colorectal cancer. The study results exceeded the historic benefits linked to approved therapies, offering new hope for a population with limited treatment options.
The international consensus statement provides critical recommendations for the cardiovascular management and follow-up of patients undergoing radiation therapy. The paper highlights the need to identify and address cardiovascular risk factors to prevent cardiotoxicity, emphasizing the importance of regular screening and treatment for ...
A new NRG Oncology clinical trial found that bupropion did not improve sexual desire in female cancer survivors. The trial evaluated the effects of extended-release bupropion on postmenopausal women with low baseline sexual desire scores.
A recent study found that despite some progress, the US academic workforce in radiation and medical oncology remains underrepresented compared to the broader US cancer population. The study emphasizes the need for continued efforts to recruit and retain diverse faculty members.
A positive correlation was found between MET gene amplification and PD-L1 expression in patients with NSCLC and no other actionable oncogenic driver. The study suggests that MET amplification up-regulates PD-L1 expression, which may impact treatment strategies for these patients.
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.
Researchers at MD Anderson Cancer Center reported that serial stereotactic body radiation therapy (SBRT) is a safe and effective treatment for oligometastatic renal cell carcinoma. The study showed promising results, with a median progression-free survival of 22.7 months and minimal toxicity.
A recent clinical trial found that a shortened course of radiation therapy after prostate removal surgery does not increase long-term side effects or lower quality of life compared to conventional treatment. Patients who underwent hypofractionated, post-operative radiation therapy experienced comparable genitourinary and gastrointestin...
Researchers analyzed the effects of small-molecule drugs on colorectal tumor cells, finding that treatment with Imipridones decreased certain cytokines and increased others. The study highlights the complexity of cytokine signaling and its potential as a biomarker for diagnosis and prognosis in colon cancer.
A study published in JAMA Oncology found that the type of cancer treatment affects the vaccine response, with chemotherapy resulting in lower antibody levels. Vaccination is still recommended for cancer patients, but optimal protection requires ongoing measures.
The new guidelines aim to improve scientific reproducibility, accurate comparisons, and avoid misinterpretations in interventional oncology studies. The panel recommended analyzing parameters such as overall survival, disease-free survival, and short-term complications per patient and procedure.
A survey of 5,589 cancer patients found widespread unawareness about immunotherapy's mechanism, efficacy, and cost. Non-oncology doctors also face challenges in keeping up with the latest developments in oncology.
Researchers have developed a new adaptive radiotherapy strategy called PULSAR, which combines radiation and immunotherapy to improve tumor control. The approach uses artificial intelligence to personalize treatment plans, allowing oncologists to replan cancer treatment in under 30 minutes.
Patients with cancer who experience clinically significant fatigue before treatment have shorter overall survival times and more side effects. Researchers analyzed four clinical trials testing lung and prostate cancer treatments, confirming that pretreatment fatigue may be an important prognostic factor in oncology.
Boston University School of Medicine has received a grant of $2.7M from the American Heart Association to study disparities in cardio-oncology and their impact on cardiovascular disease among diverse populations. The research aims to better understand the causes, consequences, treatment, and prevention of CVD among cancer patients.
The 2021 ESMO World Congress on Gastrointestinal Cancer presented new concepts in clinical trials, advances in surgery and transplant, and novel immuno-oncology mechanisms. Researchers shared findings on the effects of drug interactions in GI oncology and strategies to improve outcomes for patients with metastatic pancreatic cancer.
A new online database, TOPOGRAPH, has been developed to streamline the process of recommending therapeutic treatments in precision cancer medicine for Australian patients. The platform catalogues oncology research and provides personalized treatment recommendations based on genomic variations and biomarkers.
Researchers at Dana-Farber Cancer Institute presented numerous studies on various types of cancer, including kidney cancer, melanoma, and lung cancer. The studies focused on innovative treatments, diagnostic advances, and patient outcomes.
A new study reveals that small uveal melanomas have molecular genetic alterations, making them highly metastatic tumours. Prompt treatment can significantly increase the chances of cure for these patients.
A new UCSF study reports that cancer patients experience a deep sense of loneliness during the COVID-19 pandemic, with 53% of participants classified as lonely. The study also found higher levels of depression, fatigue, and sleep disturbance among lonely patients.
The NRG-BR001 trial found SBRT to be safe for patients with multiple metastases, with no dose-limiting toxicities and over 50% of participants alive at 2 years. The study used extensive radiation QA processes and was the first to require 3D image guidance during treatment.
City of Hope's Betty Ferrell is honored with the 2021 ONS Lifetime Achievement Award for her decades-long dedication to improving pain management and quality of life for cancer patients. With over $70 million in grant funding, she has trained millions of nurses and clinicians globally on palliative care.
A newly released position paper from ESMO and SIOPE defines a common vision for improving outcomes for AYAs with cancer in Europe. The paper highlights the key challenges of AYA care, including limited awareness of cancer biology, availability of specialist centres, and access to clinical trials.
The Heine H. Hansen Award recognizes outstanding contributions to lung cancer research and education. Johan Vansteenkiste and Fiona Blackhall are this year's recipients, known for their pioneering work in thoracic oncology, liquid biopsies and personalized medicine.
The CCE-DART project aims to develop interconnected tools to reduce the complexity of investigator-initiated trials, incorporating cutting-edge digital technologies. It will harmonize molecular multi-tier profiling platforms to precisely match patients to novel anti-cancer medicines based on genetic tumor specificities.
Researchers conducted a randomized intervention that improved continuity of care and interprofessional collaboration between lung cancer patients and their family physicians. The bidirectional exchange of patient information and care summaries led to enhanced patient and family physician perceptions of care, resulting in better outcomes.
Researchers found extremely low detection of SARS-CoV-2 on environmental surfaces in outpatient and inpatient oncology areas, including a COVID-19 floor. The study's results confirm the effectiveness of enhanced cleaning and disinfecting policies in reducing virus transmission.
The ESMO Virtual Plenaries will present original scientific data from randomised phase III and phase II oncology trials, showcasing remarkable therapeutic benefits and progress in unmet areas. The platform aims to accelerate the transition from research to practice, benefiting cancer patients worldwide.
A new study shows that liquid biopsies can detect lingering disease in patients with oligometastatic colorectal cancer, guiding treatment decisions. The biopsies identify patients who may benefit from immune therapies or targeted treatments based on mutations detected in blood samples.
The COVID-19 pandemic has had a detrimental impact on the progress of achieving gender balance in academic oncology. Disruptions to research and education have hindered the advancement of this specialty, particularly for women. The article proposes potential solutions to counteract these negative effects.
The NRG Oncology trial shows improved in-field tumor control with adaptive radiotherapy, increasing local-regional tumor control by 11% and primary tumor control by 17%. The study's results suggest individualizing radiotherapy dose prescriptions according to patient's intrinsic sensitivity for better survival outcomes.
The NRG Oncology phase II clinical trial determined that the combination of total neoadjuvant therapy with pembrolizumab and chemoradiotherapy is safe for patients with locally-advanced rectal cancer (LARC). However, it may not offer any statistically significant improvement in downstaging of the cancer at the time of surgery.
The FDA Oncology Center of Excellence has developed initiatives to address the unique challenges faced by cancer patients during COVID-19. The center provides guidance and support to healthcare professionals, enabling them to provide high-quality cancer care despite the pandemic's impact.
A randomized clinical trial demonstrated the benefits of early integration of palliative care into oncology care for patients with high-risk AML. Patients who received integrated palliative and oncology care reported significantly better quality of life and lower levels of depression, anxiety, and PTSD.
Researchers found non-pharmacological interventions such as fan therapy and bilevel ventilation to be effective in improving breathlessness in patients with advanced cancer. In contrast, medications like opioids had limited impact on symptom relief.
The new guidelines provide uniform standards for treating brain tumour complications such as epileptic attacks, brain edema, haemorrhage, or thrombosis worldwide. The initiative aims to increase patient safety and improve treatment outcomes.
Researchers report factors preventing effective launch of oncology biosimilars, including market share struggles and patent litigation lawsuits. The 'Pay-for-Delay' strategy by AMGEN and Genentech/Roche holds the market hostage.
The ESMO Immuno-Oncology Congress 2020 discussed the latest developments in cancer treatment, including adjuvant and neoadjuvant treatments, tumour microenvironments, and novel therapeutics. The event also examined the impact of COVID-19 on immunotherapy in cancer patients.
A study of UK oncology staff found that many had COVID-19 antibodies without symptoms and lost positivity after four weeks. Researchers propose routine testing for signs of current or previous infection to protect staff and cancer patients.
The study found that patients with a radio-sensitive genotype have better survival with standard radiation therapy, while those with the resistant genotype fare better with high dose radiotherapy. High dose radiotherapy is associated with shorter survival times among patients with the sensitive genotype.
A survey of nearly 400 cancer survivors found that 87% experienced sexual side effects, but most were not formally asked by their oncologist. Female patients were particularly unlikely to be discussed with. Researchers recommend using a standard questionnaire to initiate conversations and improve patient experience.
A phase II trial shows similar safety and efficacy with single- and multiple-fraction treatment for patients with limited oligometastases. The study found comparable survival rates, local control rates, and disease-free survival rates between the two treatment groups.
The ESMO Asia Virtual Congress 2020 examined the efficacy of new therapies for prevalent cancer types in the Asia-Pacific region. The scientific program featured key research areas, including neo-adjuvant immuno-oncology and molecular stratification.
The COVID-19 pandemic has posed significant financial risks to independent oncology practices. Experts propose various strategies to promote stability and survival in these vulnerable entities.
The new guideline provides options for different treatments to improve survival rates and quality of life for patients with locally advanced rectal cancer. Recommendations address patient selection, pelvic radiation treatments, integration with chemotherapy and surgery, and follow-up care.
The American Society for Radiation Oncology (ASTRO) will highlight groundbreaking studies and discussions on cancer treatment advances, COVID-19, and racial representation in radiation therapy clinical trials at its upcoming Annual Meeting.
The FDA has issued guidance on clinical trials for cancer drug development during the COVID-19 pandemic. The guidance highlights regulatory challenges and lessons learned from recent experiences. By providing this support, the FDA aims to facilitate oncology drug development in a challenging environment.
A pay-for-performance program increased prescriptions of high-quality, evidence-based cancer drugs by 5.1 percentage points without significantly changing total spending on care. The program improved the rate of high-value prescribing in oncology, leading to better patient outcomes and longer life expectancy.
Researchers at UVA Cancer Center developed a set of metrics to evaluate care provided for brain metastases, aiming to enhance treatment decisions and coordination. The findings, published in JCO Oncology Practice, will help hospitals improve their interdisciplinary treatment programs.
The MAP Congress 2020 aimed to answer the critical question of how to integrate tumour sample analysis into daily practice. Key findings highlighted actionable mutations in patient DNA for personalized treatment, with expert guidance on molecular targeting and biomarkers.
A new study published in Frontiers In Oncology found a negative association between beta-blocker use and survival outcomes in patients with HER2 positive advanced breast cancer. The research highlights a subgroup of patients whose survival outcomes are poorer and calls for further investigation to improve treatment outcomes.
A recent study found that COVID-19-related interruptions in rehabilitation care for women with breast cancer led to increased emotional distress and reduced physical activity. The study, published in Rehabilitation Oncology, surveyed 15 breast cancer survivors who experienced cancelled appointments due to the pandemic.
The COVID-19 pandemic has resulted in a huge backlog of cancer treatments and research, with delays and cancellations reported across 18 countries. Oncology professionals are also facing burnout and wellbeing damage due to the pandemic's impact on their workload and job performance.
Researchers have developed an immune-oncology approach that uses nanobodies to target cancer cells and boost the body's natural immune response. The new therapy has shown promise in treating multiple myeloma and acute myeloid leukemia, and could lead to new treatments for a range of cancers.
The COVID-19 pandemic is driving a shift in oncology clinical research, as new technologies are incorporated and old practices are revisited. This Viewpoint discusses how the pandemic may reshape clinical practice and highlight the need for rethinking oncology clinical research.
A clinical trial found that patients with IDH-mutant high-risk LGG, regardless of codeletion status, receive a survival benefit from adding postradiation chemotherapy. The study supports the use of WHO-defined molecular subgroups in predicting response to treatment.